Stock option grants awarded to Gyre (GYRE) chief financial officer
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Eastling Thomas Wilson reported acquisition or exercise transactions in this Form 4 filing.
GYRE THERAPEUTICS, INC. reported that Chief Financial Officer Thomas Wilson received multiple stock option awards on May 4, 2026. These derivative transactions are all coded as grants and reflect compensation, not open‑market buying or selling of common shares.
The awards include options to purchase 92,683 shares of common stock at $5.98 per share expiring on November 12, 2034, and other options covering 95,060 shares at $2.34, 47,530 shares at $0.93, and additional grants at $2.00 and $0.32 per share with expirations between 2028 and 2031. One option for 33,271 shares at $0.32 is held indirectly through his spouse, and one option is already fully vested, while another 92,683‑share grant vests over time starting November 13, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Eastling Thomas Wilson
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 95,060 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 47,530 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 11,882 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 33,271 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 95,060 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 92,683 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 33,271 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 95,060 shares (Direct, null);
Stock Option (Right to Buy) — 33,271 shares (Indirect, By Spouse)
Footnotes (1)
- This option is fully vested. This option represents a right to purchase 92,683 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Option grant (spouse-held): 33,271 options at $0.32
Option grant: 92,683 options at $5.98
Option grant: 95,060 options at $2.34
+4 more
7 metrics
Option grant (spouse-held)
33,271 options at $0.32
Exercise price $0.32, expiration June 7, 2028, indirect by spouse
Option grant
92,683 options at $5.98
Exercise price $5.98, expiration November 12, 2034, vests over 3+ years
Option grant
95,060 options at $2.34
Exercise price $2.34, expiration January 23, 2032, direct holding
Option grant
33,271 options at $2.00
Exercise price $2.00, expiration June 9, 2031, direct holding
Option grant
11,882 options at $2.00
Exercise price $2.00, expiration December 17, 2030, direct holding
Option grant
47,530 options at $0.93
Exercise price $0.93, expiration January 12, 2030, direct holding
Option grant
95,060 options at $0.32
Exercise price $0.32, expiration June 7, 2028, direct holding
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, Chief Financial Officer, indirect ownership, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for each derivative grant"
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Chief Financial Officer financial
"officer_title: "Chief Financial Officer" for reporting person"
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
indirect ownership financial
"ownership_type: "indirect" with nature_of_ownership "By Spouse""
vesting financial
"footnote describing one quarter vested then monthly vesting over three years"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did GYRE’s CFO report in this Form 4 filing?
The filing shows GYRE’s CFO Thomas Wilson received several stock option awards as compensation, all recorded as acquisitions of derivative securities rather than open‑market trades, increasing his rights to purchase common stock at preset exercise prices.
How many GYRE options at $5.98 were granted to the CFO?
Thomas Wilson was granted stock options covering 92,683 shares of GYRE common stock at an exercise price of $5.98 per share, with an expiration date of November 12, 2034, vesting over several years after an initial vesting date.
Are any of the GYRE CFO’s new options held indirectly?
Yes. One stock option grant for 33,271 underlying GYRE common shares at a $0.32 exercise price is reported as held indirectly, described as "By Spouse," meaning the award is attributed to his spouse for ownership purposes.
Did the GYRE CFO buy or sell common stock in the market?
No market purchases or sales are reported. All Form 4 entries are coded as option grants, meaning they are awards of rights to buy GYRE common stock in the future, not immediate open‑market trading of existing shares.
What are the key strike prices and expirations of the GYRE options?
Reported options have exercise prices of $5.98, $2.34, $2.00, $0.93, and $0.32 per share, with stated expiration dates ranging from 2028 through 2034, defining when each award ceases to be exercisable.